Trial Profile
Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment period.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Bitopertin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MOONLYTE
- Sponsors Roche
- 10 Dec 2022 This trial has been discontinued in Lithuania according to European Clinical Trials Database record.
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jan 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.